Company profile for Constellation Pharmaceuticals

NEW Drugs in Dev: 2
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics.nFounded in 2008 by seasoned scientific, medical and business leaders. Constellation was the first biopharmaceutical company to target selective regulators of epigenetic function as a potential therapeutic approach.nnResearch at Const...
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics.\nFounded in 2008 by seasoned scientific, medical and business leaders. Constellation was the first biopharmaceutical company to target selective regulators of epigenetic function as a potential therapeutic approach.\n\nResearch at Constellation and by others has shown that modulating epigenetic regulation has the potential to be a powerful avenue for the development of breakthrough new medicines for cancer and other immune-mediated diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
215 First Street, Suite 200 Cambridge, MA 02142
Telephone
Telephone
(617) 714-0555
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://medcitynews.com/2022/03/morphosys-cuts-rd-from-constellation-deal-to-focus-on-clinical-stage-cancer-drugs/

F. Vinluan MEDCITYNEWS
11 Mar 2022

https://www.fiercebiotech.com/biotech/gilead-s-immunomedics-cmo-jumps-to-aadi-as-biotech-looks-for-first-fda-approval-next-month

K. LaHucik FIERCEBIOTECH
26 Oct 2021

https://www.fiercebiotech.com/biotech/magenta-poaches-constellation-cmo-jeffrey-humphrey-after-five-month-search-setback-to-blood

Kyle LaHucik FIERCEBIOTECH
04 Oct 2021

https://www.fiercebiotech.com/biotech/magenta-poaches-constellation-cmo-jeffrey-humphrey-after-five-month-search-setback-to-blood

Kyle LaHucik FIERCEBIOTECH
04 Oct 2021

https://www.biopharmadive.com/news/morphosys-to-buy-constellation-in-17b-deal-aided-by-unusual-funding/601112/

N. Pagliarulo BIOPHARMADIVE
03 Jun 2021

https://www.globenewswire.com/news-release/2021/01/07/2155031/0/en/Constellation-Pharmaceuticals-Appoints-Brendan-Delaney-as-Chief-Commercial-Officer.html#:~:text=Constellation%20Pharmaceuticals%20Appoints%20Brendan%20Delaney%20as%20Chief%20Commercial%20Officer,-Email%20Print%20Friendly&text=January%2007%2C%202021%2009%3A30,Source%3A%20Constellation%20Pharmaceuticals%20%2C%20Inc.&text=(Nasdaq%3A%20CNST)%20today%20announced,%2C%20effective%20January%2011%2C%202021.

GLOBENEWSWIRE
07 Jan 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty